JPH0564125B2 - - Google Patents
Info
- Publication number
- JPH0564125B2 JPH0564125B2 JP59120630A JP12063084A JPH0564125B2 JP H0564125 B2 JPH0564125 B2 JP H0564125B2 JP 59120630 A JP59120630 A JP 59120630A JP 12063084 A JP12063084 A JP 12063084A JP H0564125 B2 JPH0564125 B2 JP H0564125B2
- Authority
- JP
- Japan
- Prior art keywords
- growth
- naltrexone
- tumor
- group
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 121
- 229960003086 naltrexone Drugs 0.000 claims description 121
- 206010028980 Neoplasm Diseases 0.000 claims description 102
- 241001465754 Metazoa Species 0.000 claims description 83
- 230000012010 growth Effects 0.000 claims description 67
- 102000003840 Opioid Receptors Human genes 0.000 claims description 46
- 108090000137 Opioid Receptors Proteins 0.000 claims description 46
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 28
- 229960004127 naloxone Drugs 0.000 claims description 27
- 239000003401 opiate antagonist Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 241000282412 Homo Species 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000002207 metabolite Substances 0.000 claims description 13
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
- 230000026267 regulation of growth Effects 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 5
- 239000003630 growth substance Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 70
- 238000000034 method Methods 0.000 description 41
- 238000012360 testing method Methods 0.000 description 37
- 230000000694 effects Effects 0.000 description 36
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 36
- 241000700159 Rattus Species 0.000 description 34
- 230000004083 survival effect Effects 0.000 description 34
- 102000005962 receptors Human genes 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 27
- 230000037396 body weight Effects 0.000 description 26
- 210000004556 brain Anatomy 0.000 description 25
- 230000004044 response Effects 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000008223 sterile water Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 238000011081 inoculation Methods 0.000 description 18
- 229960005181 morphine Drugs 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 14
- 230000009036 growth inhibition Effects 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 13
- 206010029260 Neuroblastoma Diseases 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 230000001133 acceleration Effects 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 102220467216 Receptor tyrosine-protein kinase erbB-3_S20Y_mutation Human genes 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 229940005483 opioid analgesics Drugs 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 229960002069 diamorphine Drugs 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 210000001638 cerebellum Anatomy 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 230000005748 tumor development Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 229940127240 opiate Drugs 0.000 description 6
- 108010049140 Endorphins Proteins 0.000 description 5
- 102000009025 Endorphins Human genes 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000011278 mitosis Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000556 factor analysis Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 239000003887 narcotic antagonist Substances 0.000 description 4
- 230000005868 ontogenesis Effects 0.000 description 4
- 210000004789 organ system Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 230000005264 electron capture Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 208000037824 growth disorder Diseases 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004283 incisor Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- XQQRNWNMEFUSMN-UTWDOOMRSA-N (4r,4as,7e,7ar,12bs)-7-hydrazinylidene-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 XQQRNWNMEFUSMN-UTWDOOMRSA-N 0.000 description 1
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical compound NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
- XETRHNFRKCNWAJ-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoyl 2,2,3,3,3-pentafluoropropanoate Chemical compound FC(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)F XETRHNFRKCNWAJ-UHFFFAOYSA-N 0.000 description 1
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- MMMIQKXEZUOHLU-UHFFFAOYSA-N CCN(CC)C(CCC(C=C1)=CC=C1OCC)C1=NC(C=CC(N=C=S)=C2)=C2N1.N=C=S Chemical compound CCN(CC)C(CCC(C=C1)=CC=C1OCC)C1=NC(C=CC(N=C=S)=C2)=C2N1.N=C=S MMMIQKXEZUOHLU-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 238000001367 Mood's median test Methods 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940068938 morphine injection Drugs 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 229940116487 naltrexone injection Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Organic Chemistry (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/598,092 US4689332A (en) | 1984-04-09 | 1984-04-09 | Growth regulation and related applications of opioid antagonists |
| US598092 | 1984-04-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60218320A JPS60218320A (ja) | 1985-11-01 |
| JPH0564125B2 true JPH0564125B2 (enExample) | 1993-09-14 |
Family
ID=24394194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59120630A Granted JPS60218320A (ja) | 1984-04-09 | 1984-06-11 | オピオイド拮抗体の生長調整関連用途 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4689332A (enExample) |
| JP (1) | JPS60218320A (enExample) |
| CA (1) | CA1228814A (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
| US5629349A (en) * | 1991-07-16 | 1997-05-13 | Minnesota State University System Through Its Mankato State University Agency | Compounds for modulating growth of infectious agents |
| DE60119696T2 (de) | 2000-03-15 | 2007-01-25 | Wolfgang Ross Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
| US7501433B2 (en) * | 2002-05-17 | 2009-03-10 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| EP3173082A1 (en) | 2002-05-17 | 2017-05-31 | Duke University | Method for treating obesity |
| CA2811272C (en) | 2003-04-08 | 2016-12-20 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
| US8017622B2 (en) | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US7429580B2 (en) | 2004-01-13 | 2008-09-30 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| JP2008514612A (ja) * | 2004-09-23 | 2008-05-08 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
| CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TWI609702B (zh) | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| JP2010522756A (ja) | 2007-03-29 | 2010-07-08 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 結晶形およびその使用 |
| EP2565195B1 (en) | 2007-03-29 | 2015-05-06 | Wyeth LLC | Peripheral opioid receptor and antagonists and uses thereof |
| PL2137191T3 (pl) | 2007-03-29 | 2016-12-30 | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
| AU2008349873B2 (en) | 2008-02-06 | 2014-02-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| LT3730132T (lt) | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| WO2018178690A1 (en) | 2017-03-28 | 2018-10-04 | LDN Pharma Limited | An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
| GB201704909D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
| GB201704911D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
-
1984
- 1984-04-09 US US06/598,092 patent/US4689332A/en not_active Expired - Lifetime
- 1984-06-11 JP JP59120630A patent/JPS60218320A/ja active Granted
- 1984-06-20 CA CA000456996A patent/CA1228814A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US4689332A (en) | 1987-08-25 |
| JPS60218320A (ja) | 1985-11-01 |
| CA1228814A (en) | 1987-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0564125B2 (enExample) | ||
| US5426112A (en) | Growth regulation and related applications of opioid antagonists | |
| Devor et al. | Reversible analgesia, atonia, and loss of consciousness on bilateral intracerebral microinjection of pentobarbital | |
| Vogt | The effect of lowering the 5‐hydroxytryptamine content of the rat spinal cord on analgesia produced by morphine | |
| Lipa et al. | Sex differences in the inhibitory effects of the NMDA antagonist, MK-801, on morphine and stress-induced analgesia | |
| CN101589026B (zh) | 治疗脑神经胶质瘤的方法 | |
| EP1100589B1 (en) | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity | |
| Lang et al. | Cardiovascular responses to injections of cholinomimetic drugs into the cerebral ventricles of unanaesthetized dogs | |
| AU736005B2 (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
| JP7026245B2 (ja) | 鎮痛活性を有するポリペプチドおよびその応用 | |
| CN118593457B (zh) | 芬戈莫德在制备治疗缺血性脑卒中口鼻吸入制剂中的应用 | |
| Puniak et al. | Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma | |
| Dewhurst | On the chemical basis of mood | |
| Yang et al. | Dopamine D2 receptors in the posterior region of the nucleus tractus solitarius mediate the central pressor action of quinpirole (LY171555) | |
| PT1223930E (pt) | Tratamento da discinesia | |
| CN117427083A (zh) | 阿洛酮糖在制备治疗阿尔兹海默病药物中的应用及药物 | |
| HUBBARD | Chemotherapy in captive marine mammals | |
| Olson et al. | Behavioral effects of D-Ala2-β-endorphin in squirrel monkeys | |
| CN103169716A (zh) | 用于治疗疼痛的复方药物组合 | |
| Veale et al. | Effects of calcium on the release of serotonin from isolated sites within the diencephalon of the cat | |
| CN101190184A (zh) | 一种微粉化固体外用局部麻醉剂及其制备方法 | |
| Strahlendorf et al. | Chronic administration of naltrexone alters central catecholamine levels but not the development of hypertension in spontaneously hypertensive rats | |
| JP2002322085A (ja) | 知的機能障害治療剤 | |
| Hamaoka et al. | Hypoplastic heart induced by neonatal hypothalamic lesions in mice | |
| CN121081450A (zh) | 杜鹃素及其衍生物的新应用 |